There has been much navel-gazing over Biogen’s Alzheimer’s disease hopeful aducanumab, with some analysts seeing approval on the cards and many others adamant that not only should it be rejected, but it should in fact not be approved on both moral and scientific grounds.

Merck has struck a deal to buy VelosBio for $2.75 billion. The takeover will give Merck control of an antibody-drug conjugate (ADC) that caused complete responses in 80% of previously treated diffuse large B-cell lymphoma (DLBCL) patients in a small clinical trial.

Initial conversion price represents a premium of approximately 50%

MIRAMAR, Fla., — NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to announce that the company has launched its new corporate website to provide investors with information on the NGIO mission, management, and pipeline for the Ii-Key vaccine platform for cancer and infectious disease. You can also learn about the company’s ongoing SARS-CoV-2 vaccine development program and collaborations.

As it gears up to launch a new CAR-T therapy in China, JW Therapeutics pulled off a $300 million (HK$2.325 billion) IPO on the Hong Kong Stock Exchange. The bulk of the funds will bankroll R&D and commercialization for its lead program, while the rest will fund the company’s earlier-stage programs.

Twelve-year-old early-stage neuro biotech Inhibikase Therapeutics has nearly halved its shares offering ahead of a now lowered IPO.

Jounce Therapeutics and its lead prospect took a hit Monday as its stopped enrollment in a phase 2 lung cancer trial. The company was testing the drug alongside Bristol Myers Squibb’s Yervoy in patients with non-small cell lung cancer, but an early look at the data showed the combo was unlikely to succeed.

FDA officials are pushing back against an executive order that will make it easier for President Donald Trump to fire federal employees, according to a report in Politico. Patrizia Cavazzoni, the acting head of the FDA’s drug center, is reportedly among the top officials to have raised concerns about Trump’s executive order.

Mayo Clinic neurologist David Knopman, M.D., has been kicked off an advisory committee assessing Biogen’s controversial Alzheimer’s disease hopeful aducanumab that’s meeting later this week.

Bristol Myers Squibb’s deucravacitinib has outperformed Amgen’s Otezla in a phase 3 clinical trial of patients with moderate to severe plaque psoriasis. The study linked deucravacitinib to improvements in symptom severity against two measures that served as the co-primary endpoints.